This bill grants emergency privileges to vehicles transporting human organs and medical personnel involved in time-sensitive procedures. It amends New Jersey's traffic laws to explicitly include these specialized transport vehicles within the category of authorized emergency vehicles. The changes allow these vehicles to operate with the same rights and exemptions as fire departments, police, and ambulances during emergency calls.
This New Jersey bill requires emergency departments at licensed general hospitals to give parents or guardians of children in mental health crises contact information for local care management organizations. These organizations are defined as county-based nonprofits that offer face-to-face support to youth with complex needs and their families. The law aims to connect families with community resources during urgent situations by ensuring this information is provided directly at the hospital. The changes will become effective 90 days after the bill is signed into law.
This New Jersey bill mandates that health insurance plans cover early-stage kidney disease screening without charging patients any deductibles, copayments, or coinsurance. The law specifically requires coverage for blood tests measuring glomerular filtration rate and urine tests checking albumin-creatinine ratios when a physician deems them medically necessary. Insurance providers must treat these screenings with the same benefits as other medical conditions, provided the patient meets clinical guidelines set by the National Kidney Foundation. The policy applies to various types of hospital and medical service contracts issued or renewed in the state after the act takes effect.
This bill establishes a $5 million grant program within the New Jersey Department of Health to improve the early detection and treatment of uterine fibroids. The funding will be distributed to organizations for conducting research, launching public awareness campaigns, and implementing screening procedures such as advanced imaging and patient navigation services. Additionally, the legislation requires the creation of a revolving fund to support these efforts and mandates that grant recipients track specific health outcomes like screening rates and diagnosis timing. The bill also directs the Department of Health to develop evidence-based strategies and training materials for healthcare providers based on the results of funded research.
This bill allows physician assistants and advanced practice nurses to verify that a prospective juror cannot serve due to medical reasons, expanding the current rule which only permits licensed physicians to provide such verification. It directly affects individuals seeking jury excusal based on health issues and the medical professionals licensed under New Jersey's Title 45 who may issue these certifications. By amending the state's jury service statute, the legislation broadens the pool of qualified healthcare providers who can confirm a juror's medical inability to serve without altering other hardship exemptions like financial difficulties or family obligations. The change takes effect immediately for any jury summons issued on or after the bill's effective date.
This bill requires health insurance plans in New Jersey to cover routine HIV testing for patients receiving care in primary care settings, emergency departments, and other appropriate health facilities. Under the new rules, HIV testing will be performed automatically unless a patient explicitly opts out, provided they have already given general consent for their medical visit. The legislation also mandates that insurance contracts cannot be issued or renewed without including these testing benefits, ensuring coverage is treated like any other medical condition.
This bill allows chambers of commerce, trade associations, and nonprofit business coalitions in New Jersey to create their own group health insurance plans for their member businesses. To encourage participation, the legislation provides a state tax credit of up to $1,000 per employee annually for businesses enrolled in these new plans, with a maximum annual limit of $20,000 per taxpayer. Additionally, the bill requires the state to launch a public awareness campaign funded by at least $500,000 to inform businesses about these coverage options and offers grants to help organizations cover the administrative costs of managing the plans.
This bill establishes a dedicated fund to manage money received from national opioid litigation settlements and appropriates up to $5 million annually for related state police initiatives. It designates the Department of Human Services as the lead agency responsible for distributing these funds to counties and municipalities while ensuring compliance with settlement terms. The legislation also creates a mechanism for the fund to earn interest and allows the department to adopt temporary regulations to oversee the allocation and reporting of these resources.
This New Jersey bill mandates that health insurance plans and Medicaid cover medically necessary tests and FDA-approved treatments designed to slow the progression of Alzheimer's disease and related disorders. The law applies to hospital service, medical service, and health service corporation contracts, as well as individual and group health insurance policies issued or renewed in the state. A key provision ensures that these specific Alzheimer's treatments are not subject to step therapy requirements, meaning patients can access them without needing to try other medications first. Additionally, the coverage must be provided at the same level as benefits for other medical conditions.
This New Jersey bill mandates that all health insurance plans cover the cost of genetic testing for individuals diagnosed with pancreatic cancer. The law applies to hospital service corporations, medical service corporations, health service corporations, and individual policies issued or renewed in the state after the effective date. Under the new rule, insurers must treat these genetic tests the same as any other medical condition, ensuring they are covered without additional restrictions. The legislation defines genetic testing broadly to include tests that analyze DNA, RNA, chromosomes, or proteins to identify mutations that guide treatment and monitoring.
